Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas

Liver International

Volumn 30, Issue 7, 2010, Pages 996-1002

  Sotiropoulos, Georgios C ^a   Miyazaki, Masaru ^b   Konstadoulakis, Manousos M ^c   Paul, Andreas ^a   Molmenti, Ernesto P ^a   Gomatos, Ilias P ^c   Radtke, Arnold ^a   Baba, Hideo A ^a   Beckebaum, Susanne ^a   Brokalaki, Eirini I ^a   Ohtsuka, Masayuki ^b   Schwartz, Myron E ^c   Broelsch, Christoph E ^a   Sgourakis, George ^a,d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CHIBA UNIVERSITY   (Japan)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d RED CROSS HOSPITAL   (Greece)

Author keywords

Cholangiocarcinoma; Cholangiocellular carcinoma; Primary liver tumours; Surgical therapy; Survival score; Tumour recurrence

Indexed keywords

ARTICLE; BILE DUCT CARCINOMA; BOOTSTRAPPING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; FEMALE; GERMANY; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; JAPAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POWER ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE; SCORING SYSTEM; SURVIVAL TIME; TUMOR BIOPSY; UNITED STATES; VALIDATION PROCESS; BILE DUCT NEOPLASMS; BLOOD; CANCER STAGING; CHOLANGIOCARCINOMA; CLINICAL TRIAL; EUROPE; EVALUATION STUDY; HEALTH STATUS INDICATOR; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; LIVER RESECTION; MONTE CARLO METHOD; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TIME; TREATMENT OUTCOME; TUMOR INVASION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; EUROPE; FEMALE; HEALTH STATUS INDICATORS; HEPATECTOMY; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MONTE CARLO METHOD; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEW YORK; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; KAPLAN-MEIER ESTIMATE;

BIOLOGICAL MARKER; CA 19-9 ANTIGEN;

EID: 77957123665     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02203.x     Document Type: Article

References (29)

1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33:1353-7.
2. Taylor-Robinson SD, Toledano MB, Arora S. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001, 48:816-20.
3. Cherqui D, Tantawi B, Alon R. Intrahepatic cholangiocarcinoma. Results of aggressive surgical management. Arch Surg 1995, 130:1073-8.
4. Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 1998, 5:41-7.
5. Madariaga JR, Iwatsuki S, Todo S. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998, 227:70-9.
6. Sasaki A, Aramaki M, Kawano K. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. Br J Surg 1998, 85:1206-9.
7. Inoue K, Makuuchi M, Takayama T. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000, 127:498-505.
8. Weimann A, Varnholt H, Schlitt HJ. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocarcinoma. Br J Surg 2000, 87:182-8.
9. Itamoto T, Asahara T, Katayama K. Hepatic resection for intrahepatic cholangiocarcinoma: relation to gross tumor morphology. Hepatogastroenterology 2001, 48:1129-33.
10. Weber SM, Jarnagin WR, Klimstra D. Intrahepatic cholangiocarcinoma: resectability, recurrence patterns, and outcomes. J Am Coll Surg 2001, 193:384-91.
11. Hanazaki K, Kajikawa S, Shimozawa N. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002, 49:311-6.
12. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002, 183:679-85.
13. Ohtsuka M, Ito H, Kimura F. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing the survival. Br J Surg 2002, 89:1525-357.
14. Lang H, Sotiropoulos GC, Dömland M. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC) - when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-years-period. Ann Surg 2005, 241:134-43.
15. Nakagawa T, Kamiyama T, Kurauchi N. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005, 29:728-33.
16. Puhalla H, Schuell B, Pokorny H. Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surg 2005, 189:173-7.
17. Lang H, Sotiropoulos GC, Sgourakis G. Operations for intrahepatic cholangiocarcinoma: single institution experience of 158 patients. J Am Coll Surg 2009, 208:218-28.
18. Miwa S, Miyagawa S, Kobayashi A. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006, 41:893-900.
19. De Oliveira ML, Cunningham SC, Cameron JL. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007, 245:755-62.
20. Shimada K, Sano T, Sakamoto Y. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007, 31:2016-22.
21. Konstadoulakis MM, Roayaie S, Gomatos IP. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008, 143:366-74.
22. Davison AC, Hinkley DV. Bootstrap Methods and their Application 1997, Cambridge, Cambridge University Press
23. Iyer RV, Gibbs J, Kuvshinoff B. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 2007, 14:3202-9.
24. Riechelmann RP, Townsley CA, Chin SN, Pond GR, Knox JJ. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007, 110:1307-12.
25. Kim ST, Park JO, Lee J. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006, 106:1339-46.
26. Lang H, Radtke A, Hindennach M. Impact of virtual tumor resection and computer-assisted risk analysis on operation planning and intraoperative strategy in major hepatic resection. Arch Surg 2005, 140:629-38.
27. Sotiropoulos GC, Malagó M, Molmenti E. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation 2005, 79:483-7.
28. Seo S, Hatano E, Higashi T. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 2008, 143:769-77.
29. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours 2002, 6th edn, West Sussex, John Wiley & Sons Ltd